Loading...
•
Sep 30, 2020
Anika Q3 2020 Earnings Report
Anika's financial performance increased due to strategic focus and acquisitions, leading to revenue diversification and growth.
Key Takeaways
Anika Therapeutics reported a 7% year-over-year revenue increase to $31.7 million in Q3 2020. The company repaid $25 million of its outstanding credit facility and continued to expand its joint preservation product portfolio.
Revenue increased 7% year-over-year to $31.7 million.
Repaid $25 million of outstanding credit facility.
Expanded global product portfolio.
Initiated enrollment in CINGAL Pilot Study and resumed enrollment in HYALOFAST Phase III clinical trial.
Anika
Anika
Forward Guidance
Anika is positioned to drive sustainable growth and value for all of its stakeholders going forward.